SCHEMBL2736110

SCHEMBL2736110

CC(C)Cc1cnc[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12328968 0.83
SCHEMBL6600780 0.83
SCHEMBL21579874 0.83 HRH3 (0.66)
SCHEMBL24199001 0.83
SCHEMBL3925179 0.83
SCHEMBL23192818 0.83
SCHEMBL23485680 0.81 HRH3 (0.63)
Hydrochloric Acid SCHEMBL1369323 0.81 HRH3 (1.00)
Hydrochloric Acid SCHEMBL20295961 0.81 HRH3 (1.00)
Hydrochloric Acid SCHEMBL20295958 0.81 HRH3 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
US-12024498-B2 Radical compounds and methods of using thereof OHIO STATE INNOVATION FOUNDATION (US) 2024-07-02 US disclosed
US-12024498-B2 Radical compounds and methods of using thereof OHIO STATE INNOVATION FOUNDATION (US) 2024-07-02 US disclosed
US-20240067701-A1 ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME REGENERON PHARMACEUTICALS, INC. 2024-02-29 US disclosed
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-12 US disclosed
US-20230372306-A1 COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR XOMA (US) LLC 2023-11-23 US disclosed
WO-2023220131-A2 PI3Kα INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
US-20230357357-A1 ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME REGENERON PHARMACEUTICALS, INC. 2023-11-09 US disclosed
US-20230331812-A1 ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME REGENERON PHARMACEUTICALS, INC. 2023-10-19 US disclosed
US-20080108617-A1 co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction GILEAD SCIENCES, INC. 2008-05-08 US disclosed
US-20070287745-A1 Laulimalide Analogs and Uses Thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-12-13 US disclosed
US-7291623-B2 Compounds that interact with kinases ALCHEMIA LIMITED (AU) 2007-11-06 US disclosed
US-7276520-B2 Bicyclic piperidine derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2007-10-02 US disclosed
US-20070213394-A1 Salvinorin derivatives and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2007-09-13 US disclosed
US-7244853-B2 Dioxanes and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-07-17 US disclosed
WO-2007075253-A2 INTEGRATION OF SAMPLE STORAGE AND SAMPLE MANAGEMENT FOR LIFE SCIENCE BIOMATRICA, INC. (US) 2007-07-05 WO disclosed
US-20070042988-A1 Antiviral phosphoramidates ROCHE PALO ALTO LLC 2007-02-22 US disclosed
US-7169760-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-01-30 US disclosed
US-20040072849-A1 Dioxanes and uses thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-04-15 US disclosed